Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you clarify what you mean by localizing production in response to tariffs? Are you building new capacity in the US? A: James Lico, President and CEO, explained that Fortive has been derisking its supply chain over the years without significant new investments. The company is accelerating existing plans to reduce reliance on China, focusing on contract manufacturing and current facilities rather than building new capacity.
Q: Why is the Test and Measurement segment experiencing such a significant decline? Is this due to delayed demand or a more permanent issue? A: James Lico noted that the decline is due to customers delaying investments amid economic uncertainty, particularly in semiconductors and electronics. The company expects recovery to be pushed into 2026, with improvements anticipated throughout the year.
Q: How are tariffs impacting Fortive's financial outlook for the year, and what mitigation strategies are in place? A: Elena Rosman, VP of Investor Relations, stated that the estimated tariff impact is around $200 million for 2025, with plans to offset about 80% through pricing and other countermeasures. Full mitigation is expected by the fourth quarter of 2025.
Q: Can you provide more detail on the performance and outlook for the Advanced Healthcare Solutions (AHS) segment? A: Elena Rosman mentioned that AHS margins typically start lower in Q1 and improve throughout the year. The segment faced FX headwinds and fewer days impacting consumables, but growth investments are expected to support margin expansion as the year progresses.
Q: What are the expectations for Fortive's regional sales performance, particularly in North America, China, and Western Europe? A: James Lico highlighted that North America is expected to be the strongest market, with good performance across various segments. China is anticipated to be down high single digits for the year, while Western Europe faces challenges, particularly in the Precision Technologies segment.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。